Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Gepefrine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 3/20 | 0.59 |
| ▸ | MAOA known ✓ | P21397 | 1/20 | 0.57 |
| ▸ | SLC6A4 known ✓ | P31645 | 1/20 | 0.57 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.57 |
| ▸ | SIGMAR1 known ✓ | Q99720 | 1/20 | 0.57 |
| ▸ | HTR2A known ✓ | P28223 | 3/20 | 0.53 |
| ▸ | HTR2B known ✓ | P41595 | 3/20 | 0.53 |
| ▸ | HTR2C known ✓ | P28335 | 2/20 | 0.53 |
| ▸ | DRD2 known ✓ | P14416 | 1/20 | 0.52 |
| ▸ | DRD1 known ✓ | P21728 | 1/20 | 0.52 |
| ▸ | ADRB1 known ✓ | P08588 | 1/20 | 0.52 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.52 |
| ▸ | TAAR1 | Q96RJ0 | 8/20 | 0.59 |
| ▸ | PNMT | P11086 | 1/20 | 0.58 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.57 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.57 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.57 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gepefrine SCHEMBL2903938 | 1.00 | TAAR1 (0.59) | TAAR1SLC6A2PNMTMAOASLC6A4 | |
| Gepefrine SCHEMBL265538 | 0.98 | TAAR1 (0.61) | TAAR1SLC6A2PNMTMAOASLC6A4 | |
| Gepefrine SCHEMBL2562808 | 0.98 | TAAR1 (0.61) | TAAR1SLC6A2PNMTMAOASLC6A4 | |
| Gepefrine SCHEMBL149774 | 0.98 | TAAR1 (0.61) | TAAR1SLC6A2PNMTMAOASLC6A4 | |
| Gepefrine SCHEMBL30011768 | 0.98 | TAAR1 (0.61) | TAAR1SLC6A2PNMTMAOASLC6A4 | |
| Gepefrine SCHEMBL6016854 | 0.85 | LMNA (0.64) | TAAR1SLC6A2PNMTMAOASLC6A4 | |
| Gepefrine SCHEMBL5599678 | 0.85 | LMNA (0.64) | TAAR1SLC6A2PNMTMAOASLC6A4 | |
| SCHEMBL4692874 | 0.85 | ADRB1 (0.53) | TAAR1SLC6A2PNMTMAOASLC6A4 | |
| SCHEMBL3067767 | 0.83 | ENPP2 (0.59) | TAAR1ENPP2KMT2AKDM4ELMNA | |
| SCHEMBL4531632 | 0.83 | ALOX15 (0.55) | TAAR1SLC6A2SLC6A3ENPP2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1732880-B1 | ASSAYS FOR AMPHETAMINE AND METHAMPHETAMINE | SIEMENS HEALTHCARE DIAGNOSTICS (US) | 2010-08-18 | — | — | EP | disclosed |
| EP-1732880-A4 | ASSAYS FOR AMPHETAMINE AND METHAMPHETAMINE | DADE BEHRING INC (US) | 2008-05-14 | — | — | EP | disclosed |
| EP-1733230-A1 | ASSAYS FOR AMPHETAMINE AND METHAMPHETAMINE USING STEREOSPECIFIC REAGENTS | DADE BEHRING INC. (US) | 2006-12-20 | — | — | EP | disclosed |
| EP-1732880-A1 | ASSAYS FOR AMPHETAMINE AND METHAMPHETAMINE | DADE BEHRING INC. (US) | 2006-12-20 | — | — | EP | disclosed |
| US-7115383-B2 | Assays for amphetamine and methamphetamine | DADE BEHRING INC. (US) | 2006-10-03 | — | — | US | disclosed |
| US-7037669-B2 | Assays for amphetamine and methamphetamine using stereospecific reagents | DADE BEHRING INC. (US) | 2006-05-02 | — | — | US | disclosed |
| WO-2005093417-A1 | ASSAYS FOR AMPHETAMINE AND METHAMPHETAMINE USING STEREOSPECIFIC REAGENTS | DADE BEHRING INC. (US) | 2005-10-06 | — | — | WO | disclosed |
| WO-2005092831-A1 | ASSAYS FOR AMPHETAMINE AND METHAMPHETAMINE | DADE BEHRING INC. (US) | 2005-10-06 | — | — | WO | disclosed |
| US-20050208604-A1 | Assays for amphetamine and methamphetamine | SIEMENS HEALTHCARE DIAGNOSTICS INC. | 2005-09-22 | — | — | US | disclosed |
| US-20050208603-A1 | Using enzyme complexes; forming antibodies; measuring signals; calibration | SIEMENS HEALTHCARE DIAGNOSTICS INC. | 2005-09-22 | — | — | US | disclosed |